Development of a Nose Cream Containing the Synthetic Antimicrobial Peptide P60.4Ac for Eradication of Methicillin-Resistant Staphylococcus aureus Carriage

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3539-3544

  Göblyös, Anikó ^a   Schimmel, Kirsten J M ^a   Valentijn, A Rob P M ^a   Fathers, Lorainne M ^a   Cordfunke, Robert A ^a   Chan, Hee Lam ^a   Oostendorp, Jaap ^a   Nibbering, Peter H ^a   Drijfhout, Jan W ^a   Hiemstra, Pieter S ^a   Hartigh, Jan Den ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antimicrobial peptides; Antimicrobial treatment; Formulation; HPLC (high performance pressure liquid chromatography) analysis, analysis; Nose cream; Peptides; Solid phase peptide synthesis; Synthesis

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CARRIER; CONTROLLED STUDY; CREAM; DOSE RESPONSE; DRUG FORMULATION; DRUG PURIFICATION; DRUG QUALITY; DRUG RELEASE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; MEASUREMENT REPEATABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOSE MUCOSA; QUALITY CONTROL; REPRODUCIBILITY; SHELF LIFE;

ANTIMICROBIAL PEPTIDES; ANTIMICROBIAL TREATMENT; FORMULATION; HPLC (HIGH PERFORMANCE/PRESSURE LIQUID CHROMATOGRAPHY) ANALYSIS, ANALYSIS; NOSE CREAM; PEPTIDES; SOLID-PHASE PEPTIDE SYNTHESIS; SYNTHESIS;

ADMINISTRATION, INTRANASAL; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NOSE; OILS; OINTMENTS; PEPTIDES; STAPHYLOCOCCAL INFECTIONS; WATER;

EID: 84883749592     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23695     Document Type: Article

References (17)

1. Bode LGM, Kluytmans JAJW, Wertheim HFL, Bogaers D, Vandenbroucke-Grauls CMJE, Roosendaal R, Troelstra A, Box ATA, Voss A, van der Tweel I, van Belkum A, Verbrugh HA, Vos MC. 2010. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 362:9-17.
2. Lam AP, Wunderink RG. 2006. Methicillin-resistant S. aureus ventilator-associated pneumonia: Strategies to prevent and treat. Semin Respir Crit Care Med 27:92-103.
3. van Belkum A, Verkaik NJ, de Vogel CP, Boelens HA, Verveer J, Nouwen JL, Verbrugh HA, Wertheim HFL. 2009. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis 199:1820-1826.
4. Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. 2009. Eradication of methicillin-resistant Staphylococcus aureus carriage: A systematic review. Clin Infect Dis 48:922-930.
5. Coates T, Bax R, Coates A. 2009. Nasal decolonization of Staphylococcus aureus with mupirocin: Strengths, weaknesses and future prospects. J Antimicrob Chemother 64:9-15.
6. Thomas CM, Hothersall J, Willis CL, Simpson TJ. 2010. Resistance to and synthesis of the antibiotic mupirocin. Nat Rev Microbiol 8:281-289.
7. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395.
8. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. 2004. Antimicrobial peptides: Mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des 10:2891-2905.
9. Hancock REW, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotech 24:1551-1557.
10. Peschel A, Sahl HG. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 4:529-536.
11. Nell MJ, Tjabringa GS, Wafelman AR, Verrijk R, Hiemstra PS, Drijfhout JW, Grote JJ. 2006. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 27, 649-660.
12. Peek FAW, Nell MJ, Brand R, Jansen-Werkhoven TM, van Hoogdalem EJ, Frijns JHM. 2009. Double-blinded, placebo-controlled study of the novel peptide OP-145 in chronic middle ear infection. ICAAC, abstract #L1-337.
13. U.S. Food and Drug Administration. Guidance for industry; Bioanalytical method validation. May 2001. http://www.fda.gov/cder/guidance/#Biopharmaceutics. 2009. Website accessed 15th February, 2010.
14. Yamaguchi Y, Sato H, Sugibayashi K, Morimoto Y. 1996. Drug release test to assess quality of topical formulations in Japanese market. Drug Dev Ind Pharm 22:569-577.
15. Croes S, Deurenberg RH, Boumans ML, Beisser PS, Neef C, Stobberingh EE. 2009. Staphylococcus aureus biofilm formation at the physiologic glucose concentration depends on the S. aureus lineage. BMC Microbiol 9:229.
16. Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK, Nuijens JH. 2001. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 69:1469-1476.
17. Kenter GG, Welters MJP, Valentijn ARPM, Löwik MJG, Berends van der Meer DMA, Vloon APG, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJM. 2008. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14:169-177.